form8_k4108.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) April 1,
2008
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-23143
|
|
13-3379479
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
777 Old Saw Mill River
Road, Tarrytown, New York
|
|
10591
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section
8 – Other Events
Item
8.01. Other Events.
Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc.
(Nasdaq: PGNX), today
announced that Wyeth has received marketing approval from Health Canada, the Canadian Regulatory Agency,
for RELISTOR™ (methylnaltrexone bromide
injection) for subcutaneous use. A copy of its press
release is attached hereto as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
99.1
Press
Release dated April 1, 2008
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A. McKinney
Chief Financial Officer, Senior
Vice President,
Finance & Operations and
Treasurer
Date: April 1,
2008